Original ArticleTreatment of G-CSF in unexplained, repeated implantation failure: A systematic review and meta-analysis
Introduction
In vitro fertilization-embryo transplant (IVF-ET) has emerged as a common treatment for infertile patients. However, the clinical pregnancy rate has been hovering around 30–40 % [1], which is a difficult bottleneck to break through. Of all the causes, repeated implantation failure (RIF) contributes much to the unsatisfactory pregnancy outcome. However, the diagnosis of RIF is not uniform since it was proposed [2]. It is generally defined as infertile women under the age of 40 who fail to obtain clinical pregnancy after transferring at least four high-quality embryos in at least three fresh or frozen cycles by IVF or intracytoplasmic sperm injection [3]. Due to variations in definitions for RIF, The incidence or prevalence of the disease is rarely reported [4]. Studies have shown that the etiologies of RIF are intricate, including maternal factors (reproductive organ lesions, endometrial receptivity, thrombotic diseases, autoimmune diseases), and embryonic factors (chromosomal abnormalities, zona pellucida sclerosis, poor embryo culture environment and embryo transfer operations), etc [5]. At present, clinicians attempt to eliminate maternal factors by correcting the abnormal anatomical structure, inhibiting the frequency of uterine contraction, and improving the endometrium receptivity, etc [6]. Besides, various methods are utilized to assess the treatment effects by means of morphological, metabonomics and genetic screening before embryo implantation, so as to improve culture and transfer strategies [7]. For RIF patients with unknown reasons, pathological factors of immune cell imbalance and abnormal cytokine secretion have become the hot shot in scholars' researches. Accordingly, immunotherapy has made considerable progress in unexplained RIF, such as granulocyte colony stimulating factor (G-CSF), intrauterine perfusion of peripheral blood monocytes, oral immunosuppressive agents, etc [8].
G-CSF is widely distributed. in various tissues and cells, such as fibroblasts, monocytes, macrophages, natural killer (NK) cells, especially NK cells in the uterus [9]. Animal and human studies have illustrated that G-CSF contributes to successful pregnancy by improving ovarian function, correcting pathological changes in the endometrium and promoting embryo implantation [10,11]. Currently, G-CSF has attracted much attention in the treatment of RIF. RCTs have been widely conducted to evaluate its efficacy but the results are with controversial. A double-blind RCT conducted by Davari Tanha F et al. showed that G-CSF did not affect clinical pregnancy rates or abortion rates [12]. However, Scarpellini et al. [13] found that the pregnancy rate in the G-CSF group was 43. 1%, significantly higher than that of 21.6 % in the control group (p < 0.001). Such inconsistencies may be due to small sample sizes, inconsistent test baselines and ethnic or regional differences.
In order to compare different research results more scientifically and objectively, scholars carried out extensive meta-analysis on this issue. However, the current meta-analysis shows many shortcomings. For example, Zhao [14] et al. published a meta-analysis on the effects of G-CSF in ART in 2016, including six studies. They reported that the pregnancy rate in G-CSF group was significant increased (RR 2.51, 95 %CI 1.36–4.63;I2 = 0%). However, this analysis combined data from different study designs (including prospective and retrospective studies) and patients (such as RIF, thin endometrium, and unselected groups), which might affect the accuracy of results. In addition, Kamath MS et al. 'S meta-analysis [15] in 2017 showed that the pregnancy rate of RIF in G-CSF group was significantly higher than that in the placebo group. Nevertheless, only two articles were included, which obviously contributed to bias in the outcome. On consideration of the controversial results and the deficiencies of today's meta-analyses, we thus conducted a meta-analysis that included as many eligible RCTs as possible, so as to valuate the therapeutic effect of G-CSF on unexplained RIF objectively and accurately.
Section snippets
Search strategy
Our study followed the Meta-analysis of Observational Studies in Epidemiology guidelines [16], and studies were investigated in the following databases from the time of inception to Nov. 2019: the China National Knowledge Infrastructure (CNKI), China Wanfang Database, China Weipu Database, Chinese biomedical literature database and PubMed, EMBASE, Cochrane library, Web of Science. The following medical subject heading (MeSH) words were combined according to different retrieval methods of each
Characteristics of the included studies
On the whole, a total of eleven out of 869 articles were selected for the final meta-analysis [[19], [20], [21], [22], [23], [24], [25], [26], [27], [28], [29]], involving twelve trails and 1035 patients with unexplained RIF, of which 525 patients were in the treatment group and 510 were in the control group(Fig. 1). Of the twelve RCTs in eleven articles, both groups received conventional treatment of IVF-ET. The treatment group recieved G-CSF additionally, and the control group received saline
The implantation rate (IR)
Totally five studies investigated IR after different intervention in the two groups, and the fixed-effect model was utilized for comparison on account of a low heterogeneity after data consolidation (I2 = 0.0 % <50 %). The results revealed that G-CSF could better increase IR than the control group [RR = 2. 346, 95 %CI (1. 615−3. 409), I2 = 0.0 %] (P < 0. 05). Subgroup analysis was conducted according to different methods of administration. Among these studies, four studies adopted intrauterine
Discussion
With the continuous development of life science and medicine, human assisted reproduction technology has made breakthroughs in many aspects, but embryo implantation, termed as "black box", is an extremely complex and delicate process regulated by various cell molecules and signaling pathways. Most studies have always regarded maternal and embryo factors as the main reason for implantation failure, but in recent years, people have focused on the immune factors, especially in patients with
Statement
The ethical approval is not necessary. Because the research form belongs to meta-analysis which is based on existing Clinical randomized controlled trials, and all the articles included have passed the ethical approval and informed consent.
Contribution
Ying Jiang and Qi Zhao were responsible for the selection of research and literature selection; Yuling Zhang and Xvwu Qian were responsible for meta-analysis; Ying Jiang and Lu Zhou were in charge of writing the draft; Jing Lin and Yan Chen were responsible for the collation of literature information, and took charge of the examination and modification of articles; Xvwu Qian was responsible for the examination and submission of articles.
Disclosure
No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication.
Fund project
Medical science and technology plan of ningbo city. Project No. 2018A18
Declaration of Competing Interest
On behalf of all authors, the corresponding author states that there are no conflicts of interest.
Acknowledgments
The authors thank all patients for their participation. Special thanks are also extended to colleagues at the department of gynecology, Ningbo Municipal Hospital of Traditional Chinese Medicine.
References (39)
- et al.
Recurrent implantation failure: definition and management
Reprod Biomed Online
(2014) - et al.
Is there a place for immunomodulation in assisted reproduction techniques?
J Reprod Immunol
(2004) - et al.
The efects of human recombinant granulocyte-colony stimulating factor treatment during in vitro maturation of porcine oocyte on subsequent embryonic development
Theriogenology
(2015) - et al.
The role of G-CSF in recurrent implantation failure-a randomized double blind placebo control trial
Placenta
(2016) Use of Granulocyte-colony stimulating factor in assisted reproductive technology: a systematic review and meta-analysis
Eur J Obstet Gynecol
(2017)- et al.
The role of G-CSF in recurrent implantation failure- a randomized double blind placebo control trial
Placenta
(2016) - et al.
Effect of colony- stimulating growth factor on outcome of frozen-thawed embryo transfer in patients with repeated implantation failure
Fertil Steril
(2016) - et al.
Granulocyte colony-stimulating factor for the treatment of recurrent miscarriage
J Reprod Immunol
(2011) - et al.
G-CSF treatment improves IVF outcome in women with recurrent implantation failure in IVF
J Reprod Immunol
(2012) - et al.
Granulocyte colony-stimulating factor as a potential inducer of ovulation in infertile women with luteinized unruptured follicle syndrome
Transl Res
(2016)
The definition of ‘recurrent implantation failure’
Reprod Biomed Online
Investigation and treatment of repeated implantation failure following IVF-ET
Hum Reprod
History of biochemical pregnancy was associated with the subsequent reproductive failure among women with recurrent spontaneous abortion
Gynecol Endocrinol
Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions
Reprod Biol Endocrinol
Successful treatment with intrauterine delivery of dexamethasone for repeated implantation failure
Am J Reprod Immunol
Remedies for recurrent implantation failure
Semin Reprod Med
Organ-specific phenotypic and functional features of NK cells in humans
Immunol Res
Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy
Fertil Steril
The use of G-CSF for implantation failure in IVF: a clinical trial[J]
Fertil Steril
Cited by (15)
Cutting-edge techniques provide insights regarding repeated implantation failure patients
2023, Reproductive BioMedicine OnlineGranulocyte colony-stimulating factor in reproductive-related disease: Function, regulation and therapeutic effect
2022, Biomedicine and PharmacotherapyCitation Excerpt :However, negative results were reported in later studies [80,81]. Several meta-analyses demonstrated that G-CSF could significantly increase the pregnancy rate of RIF patients [26,82–85]. A retrospective study compared the effect of subcutaneous G-CSF and intrauterine perfusion of G-CSF in RIF patients, they found that systemic administration of G-CSF was better than intrauterine perfusion in RIF patients [86], and their recent study demonstrated that the combination of intrauterine and intrauterine perfusion G-CSF could strengthen the role of G-CSF on pregnancy outcome [79].
Repeated implantation failure
2022, Management of Infertility: A Practical ApproachComparative efficacies of different immunotherapy regimens in recurrent implantation failure: A systematic review and network meta-analysis
2021, Journal of Reproductive ImmunologyCitation Excerpt :Currently, it is generally defined as the failure to achieve a clinical pregnancy after transfer of at least four good-quality embryos in a minimum of three frozen or fresh cycles in infertile women under the age of 40 years (Coughlan et al., 2014). For RIF patients, especially when no other cause can be identified, immune system imbalances, including elevated levels and activities of NK cells, presence of anti-phospholipid antibodies, dysregulated cytokines, imbalances in helper T cell (Th1 and Th2 reactions), and increased Th1/Th2 cell ratios have been evaluated (Achilli et al., 2018; Jiang et al., 2020). Immunotherapy has been proposed as one of the therapeutic options for RIF.
The Impact of New Immunological Therapeutic Strategies on Recurrent Miscarriage and Recurrent Implantation Failure
2021, Immunology LettersCitation Excerpt :Scarpellini et al. revealed that G-CSF could effectively treat unexplained RM patients, with the number of live births in women treated with G-CSF being 82.8% [39]. The current evidence reveals that the G-CSF positively affects the embryo implantation and clinical pregnancy rates of unexplained RIF patients via subcutaneous administration [40,41]. However, the intrauterine administration of G-CSF in RIF patients do not show beneficial effects on live birth rates [42].